INMEGEN Expands Genomic Research With New Sequencing Technology

INMEGEN expanded its technological infrastructure with the addition of a PromethION P2 sequencer. The device, developed by Oxford Nanopore Technologies, is among the most advanced third-generation sequencing technologies available, and represents a significant step for research and the development of new diagnostic methods, says Jorge Meléndez Zajgla, General Director, INMEGEN. 

“With this upgrade, INMEGEN now has the highest sequencing capacity of any research center in Mexico”, reports SSA. The new equipment is expected to enhance studies in oncology, infectious diseases, and rare conditions. It will also improve the institute's ability to design and implement rapid diagnostics tools, including intraoperative interventions that can determine the nature of tumors in real time. According to Meléndez, this capability could enable faster and more accurate identification of cancerous neoplasms, allowing for immediate clinical decision-making.

The new sequencing technology aids in early detection efforts for rare diseases in newborns, by reducing diagnostics time from days or weeks to hours or even minutes. This advancement aligns with ongoing efforts to enhance precision medicine in Mexico, affirms SSA. 

In hereditary breast and ovarian cancer syndromes associated with BRCA mutations, the equipment is expected to provide more sensitive and precise diagnoses. Additionally, it will facilitate rapid pathogen identification from blood or other fluid samples, reducing reliance on complex cultures and expediting infectious disease detection, explains Meléndez. 

Beyond diagnostics, the sequencer reinforces national preparedness for emerging diseases. Meléndez Zajgla emphasized its potential role in rapidly identifying the origins of future pandemics, contributing to more effective responses to health crises such as avian influenza and COVID-19.